Hepatitis B and C Screening Laboratory Tests
For hepatitis B screening, test HBsAg, anti-HBc, and anti-HBs; for hepatitis C screening, test anti-HCV antibody with reflex HCV RNA testing. 1, 2, 3, 4
Hepatitis B Virus Screening Tests
The 2023 CDC recommendations and 2025 EASL guidelines establish the standard screening panel 1, 2, 4:
Initial HBV Screening Panel (Three Tests):
- HBsAg (Hepatitis B surface antigen) - Detects active infection (acute or chronic)
- Anti-HBc (Hepatitis B core antibody, total) - Indicates past or current infection
- Anti-HBs (Hepatitis B surface antibody) - Indicates immunity from vaccination or resolved infection
This three-test panel is recommended for universal screening of all adults aged ≥18 years at least once in their lifetime 1, 4. The combination provides complete information about infection status, immunity, and need for vaccination.
Interpretation Algorithm:
- HBsAg positive = Active infection (proceed to HBV DNA quantification and HBeAg testing for disease staging) 2
- Anti-HBc positive alone = Past infection or occult infection (consider HBV DNA testing if immunosuppression planned) 1
- Anti-HBs positive alone = Immunity from vaccination 2
- All negative = Susceptible, needs vaccination 5
Additional HBV Tests (Not for Initial Screening):
- HBV DNA (quantitative) - Used after positive screening to assess viral load and guide treatment decisions 2
- HBeAg/Anti-HBe - Used to define disease phase in confirmed infections 2
- HBsAg quantitative - Used for treatment monitoring and defining prognosis 2
Hepatitis C Virus Screening Tests
The 2020 AASLD-IDSA guidelines establish the HCV screening approach 3:
Initial HCV Screening:
Anti-HCV antibody testing with reflex to HCV RNA PCR is the recommended screening strategy 3. This single blood draw approach prevents loss to follow-up.
Testing Algorithm:
Anti-HCV antibody (laboratory-based or point-of-care)
- If positive → Automatic reflex to HCV RNA testing
- If negative → No current infection (unless recent exposure within 6 months or immunocompromised) 3
HCV RNA by PCR (reflex test)
- If positive → Active infection requiring treatment
- If negative → Past resolved infection, no active disease 3
Important Caveats:
- Window period consideration: If exposure occurred within the prior 6 months and anti-HCV is negative, perform HCV RNA testing or repeat anti-HCV testing ≥6 months post-exposure 3
- Immunocompromised patients: Consider direct HCV RNA testing as antibody response may be impaired 3
- Reinfection monitoring: In persons previously treated or spontaneously cleared, use HCV RNA directly (anti-HCV will remain positive) 3
Additional HCV Tests (After Positive Screening):
- Quantitative HCV RNA - Document baseline viral load before treatment 3
- HCV genotype - May be considered if it alters treatment recommendations (less critical with modern pangenotypic regimens) 3
Special Population Considerations
Dialysis Patients:
- HBV: Screen with HBsAg, anti-HBs, and anti-HBc at baseline 5
- Susceptible patients (all negative): Monthly HBsAg screening
- Immune from vaccination (anti-HBs >10 IU/mL): Annual anti-HBs screening
- Immune from prior infection (anti-HBs positive + anti-HBc positive): No further testing 5
Pregnant Women:
- HBV: Universal screening recommended 6
- HCV: Screen with anti-HCV; if positive, confirm with HCV RNA and obtain liver function tests, HCV genotype, and co-infection screening (HIV, HBV, syphilis) 7
Persons at Risk for HBV Reactivation:
- Minimum screening: HBsAg and anti-HBc before immunosuppressive therapy 1
- If either positive, obtain HBV DNA quantification 1
Co-infection Screening
When HBV is detected, screen for HDV (anti-HDV), HCV (anti-HCV), and HIV (anti-HIV1/2) 2. Similarly, when HCV is detected, screen for HBV and HIV 7.
Common Pitfalls to Avoid
Do not screen with HBsAg alone - This misses past infections and immunity status, critical for vaccination decisions and reactivation risk assessment 1, 2
Do not report anti-HCV positive as "active infection" - Always confirm with HCV RNA, as 15-25% spontaneously clear infection but remain antibody-positive 3
Do not miss the window period - Recent HCV exposure (<6 months) may be antibody-negative but RNA-positive 3
Do not use anti-HBs alone to guide HBV reactivation prophylaxis - The presence of anti-HBc is more important for determining reactivation risk 1
Do not order HBeAg or HBV DNA as initial screening tests - These are for disease staging after confirmed infection, not for screening 2